

# Meth 2.0 and Opioid Use Disorder: A Collision of Epidemics

May 25, 2021 | 11:00am-12:30pm (PT)

## About the webinar

The goal of the NIDA Clinical Trials Network and Addiction Technology Transfer Center (ATTC) webinar series is to help scholars and clinicians in the addiction field stay abreast of cutting edge science.

In this session, **Larissa Mooney, MD**, one of two PIs for the Greater Southern California Node of the NIDA Clinical Trials Network, will discuss recent trends in co-occurring methamphetamine use and opioid use disorder (OUD), including overdose fatalities. Participants will also learn about the treatment approaches to address this rising comorbidity.



## Learning objectives

1. Recall at least two recent epidemiological trends in co-occurring methamphetamine use and opioid use disorder.
2. Identify at least three medical risks of co-occurring methamphetamine and opioid use.
3. Explain at least three evidence-based treatment approaches that can be utilized with patients who use both methamphetamine and opioids.

**1.5 CME or CE credits available:** *AMA PRA Category 1 Credits™*; PSY (APA); RN (CA BRN); LMFT, LCSW, LPCC, LEP (CAMFT); RADT I/II, CADC-CAS, CADC I/II, CADC-CS, LAADC (CCAPP); CATC (ACCBC/CAADE); CAODC (CADTP)

***Sponsored by the Northwest and Pacific Southwest Addiction Technology Transfer Centers (ATTCs) and the Western States Node of the NIDA Clinical Trials Network.***

Register here: <http://bit.ly/webinar-May2021>

## Accreditation

In support of improving patient care, this activity has been planned and implemented by Stanford Medicine and Northwest Addiction Technology Transfer Center. Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

## Credit Designation

### American Medical Association (AMA)

Stanford Medicine designates this Live Activity for a maximum of 1.50 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## CE Accreditation



This webinar meets the qualifications for the provision of one and one-half (1.5) continuing education credits/contact hours (CEs/CEHs). UCLA Integrated Substance Abuse Programs (ISAP) is approved by the American Psychological Association to sponsor continuing education for psychologists. UCLA ISAP maintains responsibility for this program and its content.

UCLA ISAP is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for LMFTs, LCSWs, LPCCs, and/or LEPs (Provider #64812). UCLA ISAP maintains responsibility for this program/course and its content. Course meets the qualifications for one and one-half (1.5) hours of continuing education credit for LMFTs, LCSWs, LPCCs, and LEPs as required by the California Board of Behavioral Sciences. UCLA ISAP is also an approved provider of continuing education for RADTs I/II, CADCs-CASs, CADCs I/II, CADCs-CSs, and LAADCs (CCAPP, #2N-00-445-1121), CATCs (ACCBC/CAADE, #CP40 872 C 0822), and CAODCs (CADTP, #151). Provider approved by the California Board of Registered Nursing, Provider #15455, for 1.5 contact hours. CE credit will be awarded at the conclusion of the webinar. Partial credit will not be available for those participants who arrive late or leave early.